These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 15288330)
1. Estrogen replacement therapy: effects on the cognitive functioning and clinical course of women with Alzheimer's disease. Levine AJ; Battista M Arch Clin Neuropsychol; 2004 Sep; 19(6):769-78. PubMed ID: 15288330 [TBL] [Abstract][Full Text] [Related]
2. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Amieva H; Le Goff M; Millet X; Orgogozo JM; Pérès K; Barberger-Gateau P; Jacqmin-Gadda H; Dartigues JF Ann Neurol; 2008 Nov; 64(5):492-8. PubMed ID: 19067364 [TBL] [Abstract][Full Text] [Related]
3. [Manifestations of Alzheimer's disease in daily living]. Kurz A; Haupt M; Hofmeister EM; Pollmann S; Romero B; Ulm K; Zimmer R Nervenarzt; 1991 May; 62(5):277-82. PubMed ID: 1865957 [TBL] [Abstract][Full Text] [Related]
4. [In Alzheimer's disease, the clinical expression of behavioral and psychological signs and symptoms is early and specific of neuropathological stages]. Michel BF; Luciani V; Geda YE; Sambuchi N; Paban V; Azorin JM Encephale; 2010 Sep; 36(4):314-25. PubMed ID: 20850603 [TBL] [Abstract][Full Text] [Related]
5. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. Cummings JL; Masterman DL J Clin Psychiatry; 1998; 59 Suppl 13():23-30. PubMed ID: 9771827 [TBL] [Abstract][Full Text] [Related]
6. Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin. Hamuro A; Saito S Psychogeriatrics; 2010 Dec; 10(4):198-200. PubMed ID: 21159055 [TBL] [Abstract][Full Text] [Related]
7. Anosognosia in Alzheimer's disease: association with patient characteristics, psychiatric symptoms and cognitive deficits. Kashiwa Y; Kitabayashi Y; Narumoto J; Nakamura K; Ueda H; Fukui K Psychiatry Clin Neurosci; 2005 Dec; 59(6):697-704. PubMed ID: 16401246 [TBL] [Abstract][Full Text] [Related]
8. Is functional decline necessary for a diagnosis of Alzheimer's disease? Park KW; Pavlik VN; Rountree SD; Darby EJ; Doody RS Dement Geriatr Cogn Disord; 2007; 24(5):375-9. PubMed ID: 17914262 [TBL] [Abstract][Full Text] [Related]
10. Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Mickes L; Wixted JT; Fennema-Notestine C; Galasko D; Bondi MW; Thal LJ; Salmon DP Neuropsychology; 2007 Nov; 21(6):696-705. PubMed ID: 17983283 [TBL] [Abstract][Full Text] [Related]
11. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693 [TBL] [Abstract][Full Text] [Related]
12. Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Rami L; Molinuevo JL; Sanchez-Valle R; Bosch B; Villar A Int J Geriatr Psychiatry; 2007 Apr; 22(4):294-304. PubMed ID: 16998781 [TBL] [Abstract][Full Text] [Related]
13. Reaction times and performance variability in normal aging, mild cognitive impairment, and Alzheimer's disease. Gorus E; De Raedt R; Lambert M; Lemper JC; Mets T J Geriatr Psychiatry Neurol; 2008 Sep; 21(3):204-18. PubMed ID: 18838743 [TBL] [Abstract][Full Text] [Related]
14. Rate of cognitive change in Alzheimer's disease: methodological approaches using random effects models. Gould R; Abramson I; Galasko D; Salmon D J Int Neuropsychol Soc; 2001 Nov; 7(7):813-24. PubMed ID: 11771624 [TBL] [Abstract][Full Text] [Related]
15. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Chu LW; Yik PY; Mok W; Chung CP Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606 [TBL] [Abstract][Full Text] [Related]
16. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients. Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S Alzheimers Dement; 2009 Sep; 5(5):375-9. PubMed ID: 19751916 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal assessment of deficit unawareness in Alzheimer's disease. Vasterling JJ; Seltzer B; Watrous WE Neuropsychiatry Neuropsychol Behav Neurol; 1997 Jul; 10(3):197-202. PubMed ID: 9297713 [TBL] [Abstract][Full Text] [Related]
18. [Depression and frontal dysfunction: risks for the elderly?]. Thomas P; Hazif Thomas C; Billon R; Peix R; Faugeron P; Clément JP Encephale; 2009 Sep; 35(4):361-9. PubMed ID: 19748373 [TBL] [Abstract][Full Text] [Related]
19. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects. Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580 [TBL] [Abstract][Full Text] [Related]
20. Cognitive deficits in asymptomatic first-degree relatives of Alzheimer's disease patients. Hom J; Turner MB; Risser R; Bonte FJ; Tintner R J Clin Exp Neuropsychol; 1994 Aug; 16(4):568-76. PubMed ID: 7962359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]